JPWO2020123980A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020123980A5 JPWO2020123980A5 JP2021534270A JP2021534270A JPWO2020123980A5 JP WO2020123980 A5 JPWO2020123980 A5 JP WO2020123980A5 JP 2021534270 A JP2021534270 A JP 2021534270A JP 2021534270 A JP2021534270 A JP 2021534270A JP WO2020123980 A5 JPWO2020123980 A5 JP WO2020123980A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable
- proprotein
- polypeptide
- activatable proprotein
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 229920001184 polypeptide Polymers 0.000 claims description 103
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 103
- 230000000873 masking effect Effects 0.000 claims description 68
- 102000003812 Interleukin-15 Human genes 0.000 claims description 39
- 108090000172 Interleukin-15 Proteins 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 235000018102 proteins Nutrition 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000003776 cleavage reaction Methods 0.000 claims description 21
- 230000007017 scission Effects 0.000 claims description 21
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims description 18
- 102000035195 Peptidases Human genes 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 18
- 239000004365 Protease Substances 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 6
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 102000056003 human IL15 Human genes 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108020001580 protein domains Proteins 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 230000005975 antitumor immune response Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 3
- 102000035101 Aspartic proteases Human genes 0.000 claims description 3
- 108091005502 Aspartic proteases Proteins 0.000 claims description 3
- 102000005572 Cathepsin A Human genes 0.000 claims description 3
- 108010059081 Cathepsin A Proteins 0.000 claims description 3
- 102000004225 Cathepsin B Human genes 0.000 claims description 3
- 108090000712 Cathepsin B Proteins 0.000 claims description 3
- 102100027995 Collagenase 3 Human genes 0.000 claims description 3
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 3
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 3
- 101710088083 Glomulin Proteins 0.000 claims description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 claims description 3
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims description 3
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims description 3
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 3
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 claims description 3
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims description 3
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims description 3
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims description 3
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000001399 Kallikrein Human genes 0.000 claims description 3
- 108060005987 Kallikrein Proteins 0.000 claims description 3
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 3
- 102100030417 Matrilysin Human genes 0.000 claims description 3
- 108010091175 Matriptase Proteins 0.000 claims description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 3
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 102000005741 Metalloproteases Human genes 0.000 claims description 3
- 108010006035 Metalloproteases Proteins 0.000 claims description 3
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 102100028848 Stromelysin-2 Human genes 0.000 claims description 3
- 102100028847 Stromelysin-3 Human genes 0.000 claims description 3
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 3
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024159011A JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779793P | 2018-12-14 | 2018-12-14 | |
| US62/779,793 | 2018-12-14 | ||
| PCT/US2019/066287 WO2020123980A1 (en) | 2018-12-14 | 2019-12-13 | Il-15 compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159011A Division JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513888A JP2022513888A (ja) | 2022-02-09 |
| JPWO2020123980A5 true JPWO2020123980A5 (enExample) | 2022-12-06 |
| JP7557465B2 JP7557465B2 (ja) | 2024-09-27 |
Family
ID=71075819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534270A Active JP7557465B2 (ja) | 2018-12-14 | 2019-12-13 | Ｉｌ－１５組成物およびその使用方法 |
| JP2024159011A Pending JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159011A Pending JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230045048A1 (enExample) |
| EP (1) | EP3893917A4 (enExample) |
| JP (2) | JP7557465B2 (enExample) |
| KR (1) | KR20210104060A (enExample) |
| CN (1) | CN114746105A (enExample) |
| AU (1) | AU2019395266A1 (enExample) |
| CA (1) | CA3121813A1 (enExample) |
| WO (1) | WO2020123980A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| MX2021003543A (es) | 2018-09-27 | 2021-06-23 | Xilio Dev Inc | Polipeptidos de citocinas enmascaradas. |
| JP2023506454A (ja) * | 2019-12-13 | 2023-02-16 | キュージーン インコーポレイテッド | サイトカインをベースとした生理活性化薬剤およびその使用法 |
| CA3174786A1 (en) | 2020-04-10 | 2021-10-14 | Sayantan Mitra | Activatable cytokine constructs and related compositions and methods |
| US20230250193A1 (en) * | 2020-06-17 | 2023-08-10 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| JP2023553323A (ja) | 2020-11-25 | 2023-12-21 | エクシリオ デベロップメント， インコーポレイテッド | 腫瘍特異的に切断可能なリンカー |
| CA3211924A1 (en) | 2021-03-16 | 2022-09-22 | Sayantan Mitra | Masked activatable cytokine constructs and related compositions and methods |
| US20240228585A1 (en) * | 2021-05-03 | 2024-07-11 | President And Fellows Of Harvard College | Fc-fusion protein therapeutic for the treatment of pancreatitis |
| EP4580683A2 (en) * | 2022-08-31 | 2025-07-09 | Proviva Therapeutics (Hong Kong) Limited | Il-15 procytokine antibody fusion proteins |
| AU2023338694A1 (en) * | 2022-09-08 | 2025-04-03 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| WO2024216170A2 (en) * | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025085744A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Fusion polypeptides and uses thereof |
| WO2025180355A1 (zh) * | 2024-02-27 | 2025-09-04 | 江苏奥赛康生物医药有限公司 | Il-15前药与免疫检查点抑制剂的组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1527100T3 (da) * | 2002-03-29 | 2009-09-07 | Schering Corp | Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| RU2011138951A (ru) * | 2009-02-23 | 2013-03-27 | Сайтомкс Терапьютикс, Инк. | Пропротеины и способы их применения |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2016004383A1 (en) * | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| EP3313874B1 (en) | 2015-06-26 | 2021-03-10 | University of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| CA3024509A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| SG11201903302UA (en) * | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| SG11201906213UA (en) * | 2017-01-10 | 2019-08-27 | Intrexon Corp | Modulating expression of polypeptides via new gene switch expression systems |
-
2019
- 2019-12-13 JP JP2021534270A patent/JP7557465B2/ja active Active
- 2019-12-13 CA CA3121813A patent/CA3121813A1/en active Pending
- 2019-12-13 AU AU2019395266A patent/AU2019395266A1/en not_active Abandoned
- 2019-12-13 WO PCT/US2019/066287 patent/WO2020123980A1/en not_active Ceased
- 2019-12-13 CN CN201980082406.XA patent/CN114746105A/zh active Pending
- 2019-12-13 EP EP19897286.1A patent/EP3893917A4/en active Pending
- 2019-12-13 KR KR1020217018990A patent/KR20210104060A/ko active Pending
- 2019-12-13 US US17/413,786 patent/US20230045048A1/en active Pending
-
2024
- 2024-09-13 JP JP2024159011A patent/JP2024175026A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020123980A5 (enExample) | ||
| US20250163153A1 (en) | Release segments and binding compositions comprising same | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| Fischer et al. | Bispecific antibodies: molecules that enable novel therapeutic strategies | |
| CN103687879B (zh) | 多价抗原结合fv分子 | |
| US20220098274A1 (en) | Engineered pd-1 variants | |
| WO2020061526A1 (en) | Conditionally activated target-binding molecules | |
| US20190153115A1 (en) | Chimeric polypeptide assembly and methods of making and using the same | |
| US20250270314A1 (en) | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof | |
| JPWO2020252264A5 (enExample) | ||
| CN115057936A (zh) | 异源二聚体多特异性抗体形式 | |
| JPWO2019246004A5 (enExample) | ||
| JP2023123649A5 (enExample) | ||
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| JPWO2019213517A5 (enExample) | ||
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| WO2022125694A1 (en) | Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function | |
| US20220275093A1 (en) | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide | |
| IL298815A (en) | Bispecific compositions targeting HER-2 and methods for their preparation and use | |
| KR20250133776A (ko) | 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법 | |
| JPWO2019121906A5 (ja) | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| US20250188172A1 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| US11666657B2 (en) | Protein-drug conjugates and their use in the treatment of cancers |